Sotatercept (Winrevair) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics · 2024
DOI: 10.58347/tml.2024.1702a ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins.
Abstract (Originalsprache)
The FDA has approved sotatercept-csrk (Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events in adults with WHO Group 1 pulmonary arterial hypertension (PAH).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2024). Sotatercept (Winrevair) for Pulmonary Arterial Hypertension. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1702a
Vancouver
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1702a
BibTeX
@article{euvimed2024,
title = {Sotatercept (Winrevair) for Pulmonary Arterial Hypertension},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
doi = {10.58347/tml.2024.1702a}
}
EUVIMED